Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

Pomalidomide is a distinct oral IMiD(®) immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects. The pivotal, multicenter, open-label, randomized phase 3 trial MM-003 compared pomalidomide + low-dose dexamethasone vs high-dose dexamethasone in 455 pat...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Haematologica
Main Authors: San Miguel, Jesus F., Weisel, Katja C., Song, Kevin W., Delforge, Michel, Karlin, Lionel, Goldschmidt, Hartmut, Moreau, Philippe, Banos, Anne, Oriol, Albert, Garderet, Laurent, Cavo, Michele, Ivanova, Valentina, Alegre, Adrian, Martinez-Lopez, Joaquin, Chen, Christine, Renner, Christoph, Bahlis, Nizar Jacques, Yu, Xin, Teasdale, Terri, Sternas, Lars, Jacques, Christian, Zaki, Mohamed H., Dimopoulos, Meletios A.
Format: Artigo
Sprog:Inglês
Udgivet: Ferrata Storti Foundation 2015
Fag:
Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4591766/
https://ncbi.nlm.nih.gov/pubmed/26160879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2015.125864
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker